Decades of research have identified genetic factors and biochemical pathways involved in
neurodegenerative diseases (NDDs). We present evidence for the following eight hallmarks …

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central
nervous system of unknown etiology. We tested the hypothesis that MS is caused by Epstein …

Blood-derived biomarkers for brain and spinal cord diseases are urgently needed. The
introduction of highly sensitive immunoassays led to a rapid increase in the number of …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Extracellular deposition of amyloid-β as neuritic plaques and intracellular accumulation of
hyperphosphorylated, aggregated tau as neurofibrillary tangles are two of the characteristic …

Abstract Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially
targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and …

Osteoarthritis affects over 300 million people worldwide. Here, we conduct a genome-wide
association study meta-analysis across 826,690 individuals (177,517 with osteoarthritis) and …

Our incomplete understanding of the causes and pathways involved in the onset and
progression of multiple sclerosis (MS) limits our ability to effectively treat this complex …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …